HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo
Biotron (ASX:BIT) has angered shareholders on HotCopper on Friday as the results of its latest COVID-facing trial come up dusty.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Announcements
Filter Results
Filters
[Clear]
- Price Sensitive: Yes